Catabasis Pharma (CATB) Announces CAT-2054 Phase 2a Missed Primary Endpoint in Hypercholesterolemia
Tweet Send to a Friend
Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) announced top-line results from its Phase 2a clinical trial of CAT-2054 for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
